Similar articles

• Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.

  Schirmer MA, Lüske CM, Roppel S, Schaudinn A, Zimmer C, Pflüger R, Haubrock M, Rapp J, Güngör C, Bockhorn M, Hackert T, Hank T, Strobel O, Werner J, Izbicki JR, Johnsen SA, Gaedcke J, Brockmöller J, Ghadimi BM. Schirmer MA, et al. J Natl Cancer Inst. 2016 Feb 8;108(5):djv387. doi: 10.1093/jnci/djv387. Print 2016 May. J Natl Cancer Inst. 2016. PMID: 26857392 Free PMC article.
• Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.

  Chen J, Li D, Killary AM, Sen S, Amos CI, Evans DB, Abbruzzese JL, Frazier ML. Chen J, et al. Ann Surg Oncol. 2009 Feb;16(2):431-9. doi: 10.1245/s10434-008-0220-8. Epub 2008 Nov 20. Ann Surg Oncol. 2009. PMID: 19020940 Clinical Trial.
• Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer.

  Okazaki T, Jiao L, Chang P, Evans DB, Abbruzzese JL, Li D. Okazaki T, et al. Clin Cancer Res. 2008 Apr 1;14(7):2042-8. doi: 10.1158/1078-0432.CCR-07-1520. Clin Cancer Res. 2008. PMID: 18381943 Free PMC article. Clinical Trial.
• Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.

  Ruess DA, Görgülü K, Wörmann SM, Algül H. Ruess DA, et al. Drugs Aging. 2017 May;34(5):331-357. doi: 10.1007/s40266-017-0453-y. Drugs Aging. 2017. PMID: 28349415 Review.
• Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.

  Sclafani F, Iyer R, Cunningham D, Starling N. Sclafani F, et al. Crit Rev Oncol Hematol. 2015 Sep;95(3):318-36. doi: 10.1016/j.critrevonc.2015.03.008. Epub 2015 Apr 15. Crit Rev Oncol Hematol. 2015. PMID: 25921418 Review.